MegaPro Biomedical Co

MegaPro Biomedical Co EBITDA Margin

The EBITDA Margin of MegaPro Biomedical Co (6827.TWO) as of Nov 11, 2026 is -1.29 M %. In the previous year, EBITDA Margin was -780,483.33 % — a change of 64.91% (lower).

EBITDA Margin

-1.29 M %

YoY

64.91%

Last updated:

EBITDA Margin of MegaPro Biomedical Co is 2024 -1.29 M % . EBITDA Margin of MegaPro Biomedical Co was 2023 -780,483.33 % . It decreases by 64.91% lower compared to the previous year.

The MegaPro Biomedical Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2020
-2,010.08 TWD
Jan 1, 2023
-780,483.33 TWD
Jan 1, 2024
-1.29 M TWD
The MegaPro Biomedical Co EBITDA Margin history
YEAREBITDA MarginYoY
-1.29 M %+64.91%
-780,483.33 %+38,728.43%
-2,010.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

MegaPro Biomedical Co Stock analysis

What does MegaPro Biomedical Co do? MegaPro Biomedical Co., Ltd. generates revenue through its development of drug ingredients utilizing nanoparticle and nanocell technology platforms. The company's primary products are MPB-1514, MPB-1523, MPB-1734, and MPB-2043, each targeting specific medical conditions. MPB-1514 treats anemia in chronic kidney disease patients via intravenous injection, while MPB-1523 diagnoses hepatocellular carcinoma through intravenous administration. MPB-1734 addresses solid tumors with intravenous treatment, and MPB-2043 aids in diagnosing metastases in peripheral lymph nodes of cancer sites. These products are sold to healthcare providers and medical institutions requiring advanced diagnostic and therapeutic solutions. The company focuses on two core technology platforms: nanoparticle and nanocell, which underpin its product development. Its product portfolio targets chronic kidney disease, hepatocellular carcinoma, solid tumors, and cancer metastasis diagnostics. These applications are directed toward medical professionals and facilities specializing in oncology and nephrology. The firm's revenue model relies on the commercialization of these specialized drug ingredients for targeted medical treatments and diagnostics. MegaPro Biomedical's products are designed for intravenous use across various medical conditions, positioning the company within the biotechnology sector. Its revenue streams come from the sale of these proprietary drug ingredients to hospitals, clinics, and research institutions. The company's market segments include healthcare providers treating kidney disease, cancer diagnostics, and oncology-focused medical facilities seeking innovative therapeutic solutions. MegaPro Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MegaPro Biomedical Co stock

EBITDA Margin of MegaPro Biomedical Co is -1.29 M % in 2024.

EBITDA Margin of MegaPro Biomedical Co changed from -780,483.33 % to -1.29 M %, representing a 64.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin MegaPro Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's MegaPro Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — MegaPro Biomedical Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — MegaPro Biomedical Co